Why the study?
Does triple therapy (aspirin, clopidogrel, OAC) compared to other antithrombotic regimens affect the rate of bleeding and thromboembolic complications in patients with AF undergoing PCI?
Does triple therapy (aspirin, clopidogrel, OAC) compared to other antithrombotic regimens affect the rate of bleeding and thromboembolic complications in patients with AF undergoing PCI?
In patients with AF undergoing PCI, antithrombotic therapy is associated with a high rate of major bleeding (11.5%) and thromboembolic events (5.3%), highlighting the need for individualized risk-benefit assessment.
Answers are grounded in this paper and cite their sources.
High event rates in AF-PCI patients highlight bleeding-thromboembolism trade-offs; supports individualized assessment but leaves optimal regimen open.
The aim of this study was to evaluate the rate of bleeding, thromboembolic complications, and the rate of stent thrombosis or restenosis in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). In this retrospective analysis, we included patients with AF who underwent PCI with stent implantation from 2003 to 2006. Combinations of aspirin, clopidogrel, and oral anticoagulation with phenprocoumon (OAC) were used for antithrombotic management. Follow-up was performed by telephone interview. Adverse events (AEs) were defined as major bleedings, stroke/transient ischaemic attack, peripheral embolism, stent thrombosis, or restenosis. One hundred and seventeen patients (85 men, mean age 72.0 +/- 8.2 years) were included in the study. Fifty-five patients (47%) received drug-eluting stents, 62 patients (53%) bare-metal stents. After coronary intervention, 53 patients (45.3%) received a combination of aspirin, clopidogrel, and OAC, 64 (54.7%) patients received other antithrombotic regimens. Eighteen patients died during follow-up, 11 patients presumably of cardiac and 7 patients of non-cardiac causes. In total, 26 AEs occurred in 24 of 113 patients (21.2%) during follow-up: 13 major bleedings, 6 cardioembolic complications, 3 stent thromboses, and 4 restenoses. The present study demonstrates an 11.5% rate of major bleedings, a 5.3% rate of thromboembolic events, and a 2.7% rate of stent thromboses in the high-risk group of patients with AF and coronary stent implantation. The decision on different antithrombotic treatment regimens needs to be based on the patients' individual risk until further prospective studies have evaluated the risk-benefit profile of a standardized approach of triple therapy in this high-risk patient group.
No takes yet. Share an insight, caveat, or question.
Halbfaß et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: